Leonard Weiner, MD
Distinguished Service Professor of Pediatrics
Professor of Pathology
Division Chief of Infectious Disease
Division Chief of Pediatric and Adolescent Infectious Disease/Immunology Center
Division Chief of Pediatric Designated HIV Center
Pediatric Infectious Diseases
Adults and Children
CLINICAL INTERESTS AND APPROACH TO CARE
Pediatric infections, immunizations, Pediatric HIV, new antibiotics
A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Infants
A Phase 3, Multi-center, Open-Label, Randomized, Comparator-Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral naïve HIV-1 infected adolescents and children aged ≥6 to <18 years
Analysis of Existing Newborn Screening Specimens from Children Diagnosed with B Cell Immunodeficiencies or Lymphopenia
A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Different Formulations of V114 in Healthy Adults and Infants
A retrospective chart review of disease markers and treatment measures in pediatric Hepatitis A, B and C patients to identify consistent disease parameters for use in clinical management.
A phase IIIA, randomized, observer-blind, controlled, multinational study to evaluate the safety and immunogenicity of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck & Co., Inc.s MMR vaccine (M-M-R®II or VaxPro), as a first dose, both co-administered with Varivax, Havrix (all subjects) and Prevnar 13 (US subset) in healthy children 12 to 15 months of age.
A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects with Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms.
A Phase 2/3Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR) Containing a Ritinavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects.
A Phase 2/3Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK) Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co), Administered with an Optimized Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Viroligically Suppressed Pediatric Subjects.
An Open Label, Randomized, Adaptive, Two-Arm, Multicenter Trial to Evaluate Pharmackinetics and Pharmacodynamics of Two Doses of Oseltamivir (Tamilflu) in the Treatment of Influenza in Immunocompromised Children, Less than 13 Years of Age, with Confirmed Influenza Infection.
DISEASES & CONDITIONS TREATED
Bacterial Meningitis in Children
HIV Infection and AIDS
Infections of Bones and Joints
Viral Infections in Children
Viral Meningitis in Children
Yeast Infection or Candidiasis
Upstate University Hospital - Downtown Campus
750 East Adams Street
Syracuse, NY 13210
CLINICAL SECTION AFFILIATIONS
CURRENT HOSPITAL PRIVILEGES
Upstate University Hospital